News & Updates

Show Multimedia Only

EUS-RFA eases symptoms in patients with insulinomas

20 Apr 2026

Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) offers a minimally invasive resolution of symptoms in patients with a suspicion of insulinomas and has a favourable safety profile relative to surgery, according to a study. However, its long-term efficacy warrants further investigation.

EUS-RFA eases symptoms in patients with insulinomas

20 Apr 2026

MACS patients suffer sleep impairment similar to those with Cushing syndrome

20 Apr 2026

Patients with mild autonomous cortisol secretion (MACS) may experience poor sleep quality comparable to those with Cushing syndrome (CS), reports a study. Notably, sleep impairment appears to be more common among younger women with higher clinical MACS severity.

MACS patients suffer sleep impairment similar to those with Cushing syndrome

20 Apr 2026

SURPASS-CVOT: Tirzepatide better than dulaglutide for cardiorenal outcomes

17 Apr 2026 by

Treatment with tirzepatide, a dual GLP-1* and GIP** agonist, significantly improves cardiovascular and renal outcomes in patients with diabetes and atherosclerotic cardiovascular disease (ASCVD) compared with dulaglutide, according to a post hoc analysis of the SURPASS-CVOT trial presented at ACC.26.

SURPASS-CVOT: Tirzepatide better than dulaglutide for cardiorenal outcomes

17 Apr 2026

MetS risk higher in children with primary hypertension

16 Apr 2026

Children with hypertension, particularly those with primary hypertension, are vulnerable to developing metabolic syndrome (MetS), reveals a study.

MetS risk higher in children with primary hypertension

16 Apr 2026

Can prednisolone be used in place of hydrocortisone in adrenal insufficiency?

13 Apr 2026 by

The use of once-daily, low-dose prednisolone for glucocorticoid replacement in adrenal insufficiency yields substantial improvements in bone turnover and cardiometabolic health markers compared with multiple-dose hydrocortisone, according to the results of a crossover randomized clinical trial.

Can prednisolone be used in place of hydrocortisone in adrenal insufficiency?

13 Apr 2026

Semaglutide confers ASCVD risk factor benefits in high-risk patients

11 Apr 2026

Treatment with semaglutide yields early and sustained improvements in multiple atherosclerotic cardiovascular disease (ASCVD) factors in high-risk patients with type 2 diabetes (T2D) and ASCVD and/or chronic kidney disease (CKD), according to a post hoc analysis of the SOUL trial.

Semaglutide confers ASCVD risk factor benefits in high-risk patients

11 Apr 2026

Anthocyanin may reverse IGT by improving insulin sensitivity

10 Apr 2026

Supplementation with anthocyanin improves insulin sensitivity, which could then significantly reverse impaired glucose tolerance (IGT), reports a study.

Anthocyanin may reverse IGT by improving insulin sensitivity

10 Apr 2026

Finerenone protects kidneys in patients with T1D + CKD

09 Apr 2026 by

Finerenone significantly reduces albuminuria vs placebo and maintains a manageable safety profile in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD) receiving background therapy with renin-angiotensin-aldosterone system inhibitors (RAASi), the phase III FINE-ONE trial has shown. These findings represent an important step forward since RAASi were introduced for renoprotection in T1D more than 30 years ago.

Finerenone protects kidneys in patients with T1D + CKD

09 Apr 2026

C-index predicts adverse outcomes, death in anticoagulated patients with AF

08 Apr 2026

The conicity index (C-index) appears to be the most robust and most consistent prognostic value among adiposity indices in anticoagulated patients with atrial fibrillation (AF), suggests a study.

C-index predicts adverse outcomes, death in anticoagulated patients with AF

08 Apr 2026

SGLT2 inhibitor vs GLP-1 RA: Which is better for CKD patients with diabetes?

08 Apr 2026

Initiation of an SGLT2 inhibitor, relative to a GLP-1 receptor agonist (RA), results in a lower risk of adverse kidney events among patients with stage 2 diabetes and stage 4‒5 chronic kidney disease (CKD), with similar cardiovascular and mortality risks, a study has shown.

SGLT2 inhibitor vs GLP-1 RA: Which is better for CKD patients with diabetes?

08 Apr 2026

News & Updates

Showing Endocrinology articles

Showing

Specialty:

EUS-RFA eases symptoms in patients with insulinomas

EUS-RFA eases symptoms in patients with insulinomas

MACS patients suffer sleep impairment similar to those with Cushing syndrome

MACS patients suffer sleep impairment similar to those with Cushing syndrome

SURPASS-CVOT: Tirzepatide better than dulaglutide for cardiorenal outcomes

SURPASS-CVOT: Tirzepatide better than dulaglutide for cardiorenal outcomes

MetS risk higher in children with primary hypertension

MetS risk higher in children with primary hypertension

Can prednisolone be used in place of hydrocortisone in adrenal insufficiency?

Can prednisolone be used in place of hydrocortisone in adrenal insufficiency?

Semaglutide confers ASCVD risk factor benefits in high-risk patients

Semaglutide confers ASCVD risk factor benefits in high-risk patients

Anthocyanin may reverse IGT by improving insulin sensitivity

Anthocyanin may reverse IGT by improving insulin sensitivity

Finerenone protects kidneys in patients with T1D + CKD

Finerenone protects kidneys in patients with T1D + CKD

C-index predicts adverse outcomes, death in anticoagulated patients with AF

C-index predicts adverse outcomes, death in anticoagulated patients with AF

SGLT2 inhibitor vs GLP-1 RA: Which is better for CKD patients with diabetes?

SGLT2 inhibitor vs GLP-1 RA: Which is better for CKD patients with diabetes?